Temocaprilat

TargetMol
Product Code: TAR-T20689
Supplier: TargetMol
CodeSizePrice
TAR-T20689-1mg1mg£346.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T20689-2mg2mg£453.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T20689-5mg5mg£631.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T20689-1mL1 mL * 10 mM (in DMSO)£742.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T20689-10mg10mg£871.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T20689-25mg25mg£1,259.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T20689-50mg50mg£1,669.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T20689-100mg100mg£2,231.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃

Images

1 / 1

Further Information

Bioactivity:
Temocaprilat is an Angiotensin-converting Enzyme (ACE) inhibitor. Temocaprilat is effectively excreted in bile via cMOAT that is deficient in EHBR and that many of other ACE inhibitors have low affinity for cMOAT.
CAS:
110221-53-9
Formula:
C21H24N2O5S2
Molecular Weight:
448.55
Pathway:
Metabolism
Purity:
0.9688
SMILES:
OC(=O)CN1C[C@H](SC[C@H](NC(CCc2ccccc2)C(O)=O)C1=O)c1cccs1
Target:
Angiotensin-converting Enzyme (ACE)

References

1. Ishizuka H, et al. Temocaprilat, a novel angiotensin-converting enzyme inhibitor, is excreted in bile via an ATP-dependent active transporter (cMOAT) that is deficient in Eisai hyperbilirubinemic mutant rats (EHBR). J Pharmacol Exp Ther. 1997 Mar;280(3):1304-11. 2. Yasunari K, et al. Converting enzyme inhibitor temocaprilat prevents high glucose-mediated suppression of human aortic endothelial cell proliferation. J Cardiovasc Pharmacol. 2003 Dec;42 Suppl 1:S55-60. 3. P?chler K, et al. Pharmacokinetics of temocapril and temocaprilat after 14 once daily oral doses of temocapril in hypertensive patients with varying degrees of renal impairment. Br J Clin Pharmacol. 1997 Dec;44(6):531-6. 4. Ishizuka H, et al. Transport of temocaprilat into rat hepatocytes: role of organic anion transporting polypeptide. J Pharmacol Exp Ther. 1998 Oct;287(1):37-42.